Rat VEGFC / VEGF-C (aa 108-223) Protein

Vascular endothelial growth factor C Protein Datasheet

VEGFC / VEGF-C Protein Product Information

• Synonym: VEGFC
• Protein Construction: A DNA sequence encoding the rat VEGFC(O35757) (Ala108-Arg223) was expressed, fused with the Fc region of human IgG1 at the N-terminus.
• Source: Rat
• Expression Host: Human Cells

VEGFC / VEGF-C Protein QC Testing

• Purity: > (73+25.1) % as determined by SDS-PAGE
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Glu
• Molecular Mass: The recombinant Rat VEGFC/Fc comprises 376 amino acids and has a predicted molecular mass of 41.5 kDa. The apparent molecular mass of the protein is approximately 44 and 34 kDa in SDS-PAGE under reducing conditions.
• Formulation: Lyophilized from sterile PBS, pH7.4.
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: VEGFC / VEGF-C protein

VEGFC / VEGF-C Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

VEGFC / VEGF-C Protein Description

Vascular endothelial growth factor (VEGF)-C is a member of the VEGF family, a group of polypeptide growth factors which play key roles in the physiology and pathology of many aspects of the cardiovascular system, including vasculogenesis, hematopoiesis, angiogenesis and vascular permeability. While VEGFC is homologous to other members of the VEGF/PDGF family, it contains the C-terminal propeptide which has an unusual structure with tandemly repeated cysteine-rich motifs. Upon biosynthesis, VEGFC is secreted as a non-covalent momodimer in an anti-parellel fashion. VEGF signalling in endothelial cells occurs through three tyrosine kinase receptors (VEGFRs) expressed by endothelial cells and hematopoietic precursors, and VEGF-C is a ligand for two receptors, VEGFR-3 (Flt4), and VEGFR-2. It is indicated that VEGFC undergoes a complex proteolytic maturation generating a variety of processed secreted forms with increased activity toward VEGFR-3, but only the fully processed form could activate VEGFR-2. VEGFC may function in angiogenesis of the venous and lymphatic vascular systems during embryogenesis, and also in the maintenance of differentiated lymphatic endothelium in adults.

References

1. Mandriota SJ. Et al., 1999, J Soc Biol. 193 (2): 159-63.
2. Joukov V. et al., 1996, EMBO J. 15 (2): 290-98.
3. Vladimir Joukov. et al., 1997, The EMBO Journal. 16 (13): 3898-911.